Research Aims to Improve Cancer Treatments Using Artificial Intelligence

A European research consortium, OPTIMA, comprising 39 partners from 13 countries, has launched an initiative to leverage artificial intelligence (AI) for enhancing cancer treatments. The project's objective is to develop individualized treatment recommendations for patients diagnosed with breast, lung, and prostate cancer.

Dr. Hagen Krüger, Medical Director of Oncology at Pfizer Germany and project lead for OPTIMA, explains that the initiative addresses the growing challenge for physicians in selecting optimal therapies amidst an increasingly complex medical landscape. OPTIMA utilizes "Real World Data" and AI technologies to supplement existing treatment guidelines, particularly for patient subgroups with limited data from clinical trials.

The project gathers and analyzes treatment data from over 200 million patients, in compliance with GDPR, sourced from hospitals, electronic health records, cancer registries, and pharmaceutical companies. AI is employed to scrutinize these extensive datasets for patterns and identify comparable patient cases. The aim is to provide clinicians with AI-driven tools that assist in selecting personalized treatments in collaboration with patients.

The OPTIMA project, initiated in 2021 with over €20 million in funding, seeks to revolutionize cancer care across Europe. It is slated for integration into clinical practice by 2026, intending to establish the first interoperable, EU-wide data infrastructure for cancer research.